ESMO Highlights

October 2020, Vol 1, No 2 — October 29, 2020
Two phase 2 studies of futibatinib, a highly selective irreversible fibroblast growth factor receptor (FGFR)1-4 inhibitor, analyzed data from the FOENIX-CCA2 clinical trial and were presented at the 2020 virtual meeting of the European Society for Medical Oncology (ESMO).
Read More

October 2020, Vol 1, No 2 — October 29, 2020
One year after the FDA approval of the combination of lenvatinib (Lenvima), a multikinase inhibitor, plus the immunotherapy pembrolizumab (Keytruda), a PD-1 inhibitor, for the treatment of patients with advanced endometrial cancer that is not microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR), results of the LEAP-005 study showed that several other advanced solid tumors, including biliary tract cancer, may also respond to this combination. The results of the LEAP-005 study were presented at the 2020 virtual meeting of the European Society for Medical Oncology (ESMO).
Read More

October 2020, Vol 1, No 2 — October 29, 2020
Many oncologists and patients believe that precision medicine holds the promise of bypassing the traditional one-size-fits-all approach in oncology, its real-world use is not yet meeting up to its high hopes. On August 24, 2020, the European Society for Medical Oncology (ESMO) released the first recommendations from a scientific society about the use of multigene next-generation sequencing (NGS).
Read More

October 2020, Vol 1, No 2 — October 29, 2020
The multidrug combination of toripalimab, a new PD-1 inhibitor, plus lenvatinib (Lenvima), a multikinase inhibitor, and the chemotherapy drugs gemcitabine and oxaliplatin demonstrated promising efficacy in patients with advanced, unresectable intrahepatic cholangiocarcinoma (CCA), according to results of a phase 2 clinical trial presented at the 2020 virtual meeting of the European Society for Medical Oncology.
Read More

Page 2 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: